ReviewJournal of diabetes and its complications
New options for the treatment of obesity and type 2 diabetes mellitus (narrative review).
Review in Journal of diabetes and its complications. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022Guideline
- Type 2 Diabetes Mellitus in Class II and III Obesity: Prevalence, Associated Factors, and Correlation between Glycemic Parameters and Body Mass Index.International journal of environmental research and public health · 2020Trial
- The Association between Eating Traits and Weight Change after a Lifestyle Intervention in People with Type 2 Diabetes Mellitus.Journal of diabetes research · 2018Trial
- Clinical characteristics and treatment compounds of obesity-related kidney injury.World journal of diabetes · 2024Review
- A Comparative Study of the Effect of Two Procedures of Classic Roux-en-Y and Omega Bariatric Surgery on the Control and Management of Diabetes.Advanced biomedical research · 2022Article
- Can mHealth Revolutionize the Way We Manage Adult Obesity?Perspectives in health information managemen · 2017Review
- Blood-Brain Barrier Disruption and Neurovascular Unit Dysfunction in Diabetic Mice: Protection with the Mitochondrial Carbonic Anhydrase Inhibitor Topiramate.The Journal of pharmacology and experimental therapeutics · 2016Article
- Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action.Current obesity reports · 2015Review
- Antiobesity pharmacotherapy for patients with type 2 diabetes: focus on long-term management.Endocrinology and metabolism (Seoul, Korea) · 2014Review
- Testosterone and weight loss: the evidence.Current opinion in endocrinology, diabetes, and obesity · 2014Review
- Hypoglycemia after Roux-en-Y gastric bypass: the BOLD experience.Obesity surgery · 2014Article
- Obesity and outpatient rehabilitation using mobile technologies: the potential mHealth approach.Frontiers in psychology · 2014Article
- Management of obesity and cardiometabolic risk - role of phentermine/extended release topiramate.Diabetes, metabolic syndrome and obesity : targets and therapy · 2014Review
- Effects of long-term testosterone therapy on patients with "diabesity": results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes.International journal of endocrinology · 2014Article
- A complications-based clinical staging of obesity to guide treatment modality and intensity.Current opinion in endocrinology, diabetes, and obesity · 2013Review
- Metabolic syndrome in schizophrenia: theoretical, clinical and translational perspectives.Indian journal of psychological medicine · 2013Article
- New tools for weight-loss therapy enable a more robust medical model for obesity treatment: rationale for a complications-centric approach.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical EndocrinologistsReview
- Prevalence of poor glycemic and blood pressure control and pattern of drug use among primary health-care outpatients in Al Ahsa Saudi Arabia.International journal of health sciencesArticle
- Gestational diabetes mellitus as a risk factor for future Type-2 diabetes mellitus: An experience from a tertiary care diabetes hospital, Karachi - Pakistan.Pakistan journal of medical sciencesArticle
- Botanicals and translational medicine: a paradigm shift in research approach.Nutrition (Burbank, Los Angeles County, Calif.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Moderate weight loss (>5%), which has been associated with improvements in glycemic parameters in patients with dysglycemia, also reduces the presence of other comorbidities, including dyslipidemia and hypertension, culminating in a reduced risk of cardiovascular disease. Lifestyle changes are the recommended preliminary approach to weight loss, with an initial weight-loss goal of 10% of body weight achieved over 6 months at a rate of 1-2 pounds per week selected as an appropriate target to decrease the severity of obesity-related risk factors. Implementing and maintaining the lifestyle changes associated with weight loss can, however, be challenging for many patients. Therefore, additional interventions sometimes may be necessary. Bariatric surgery can also be a highly effective option for weight loss and comorbidity reduction, but surgery carries considerable risks and is still applicable only to selected patients with type 2 diabetes. Thus, attention is turning to the use of weight-loss medications, including 2 recently approved compounds: twice-daily lorcaserin and a once-daily combination of phentermine and topiramate extended-release, both shown to be safe and effective therapies in the management of obesity in patients with type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.